Rexahn Pharma (RNN) Shows Early Gains; FDA Grants RX-3117 Orphan Drug Designation
Tweet Send to a Friend
Rexahn Pharma (NYSE: RNN) is continuing higher following a 0.1 percent gainer yesterday.On Wednesday night, Rexahn affirmed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
